Education and Training
Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF(Tumor Necrosis Factor)Therapy
A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Vedolizumab
Eligibility
Inclusion Criteria:
- adult patients (>18 years old)
- clinical diagnosis of inflammatory bowel disease (Ulcerative Colitis)
- clinical indication for biologic therapy
- naive or failed anti-TNF therapy previously
Exclusion Criteria:
- patients allergic or intolerant to vedolizumab,
- past use of vedolizumab;
- patient unable to give consent to enter the study
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
John Gubatan, MD
650-736-5555
Not Recruiting